Outliers: The FDA follows the EMA [BE/BA News]
on Feb 26, the FDA published a new draft Guidance
Bioavailability Studies Submitted in NDAs or INDs — General Considerations.As usual the
Interesting that between the paragraphs
Subjects with pre-dose plasma concentrationsand
Data deletion because of vomitingthere is a new one (p 27, lines 952–961):
If any data are identified as statistical outliers, sponsors should not remove the data from the statistical analysis of BA studies solely based on this fact. The only instance where outlier data can be removed from the statistical analysis of a BA study is when there is coinciding documentation demonstrating a protocol violation (e.g., real-time documentation of a sample processing error as opposed to a retrospective investigation based on the analytical results). Data from re-dosing studies are not considered as evidence to support the removal of outlier data from the statistical analysis. Data from all subjects should be submitted, and potential outliers should be flagged with appropriate documentation as part of the submission.
I expect a similar move in the ANDA-guidance.
- According to the docket folder 20 comments were received. Then we read:
This count refers to the total comment/submissions received on this docket, as of 11:59 PM yesterday. Note: Agencies review all submissions, however some agencies may choose to redact, or withhold, certain submissions (or portions thereof) such as those containing private or proprietary information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign.
Oops. Only one is public.
Dif-tor heh smusma 🖖🏼 Довге життя Україна!
The quality of responses received is directly proportional to the quality of the question asked. 🚮
- Outliers: The FDA follows the EMAHelmut 2019-03-05 01:24 [BE/BA News]
- Outliers: The FDA follows the EMA jag009 2019-03-06 19:23